EMR

PRICE UNAVAILABLE

Fundamentals score NEUTRAL on a 34.6x trailing P/E, 12.7% return on equity, 3.0% year-over-year revenue growth. The equity risk premium sits at -1.8 percentage points versus the 10-year Treasury — the earnings yield trails bonds at the current valuation. EMR also trades on-chain as the tokenized asset EMRon on Ondo Global Markets, last at $156.39 (+0.24% versus the underlying stock).

The xBullRadar terminal reads EMR across four signals — X/Twitter sentiment (via Grok), technicals, fundamentals, and equity risk premium — and fuses them into a single BUY / SELL / NEUTRAL verdict.

X SENTIMENT

Live Grok-powered X/Twitter sentiment for EMR is available inside the terminal.

UNLOCK

TECHNICAL—

Insufficient price history.

FUNDAMENTALNEUTRAL

VALUATION: SELL
PROFITABILITY: NEUTRAL
GROWTH: BUY
HEALTH: NEUTRAL
CONSISTENCY: BUY

RISK PREMIUM-1.8%

P/E (TTM): 34.6
ROE: 12.7%
NET MARGIN: 13.8%
REV GROWTH YoY: 3.0%
DEBT/EQUITY: 0.68

TOKENIZED RWAEMRonTOKEN $156.39STOCK $156.01PREM +0.24%TRADE ON ONDO

TRADE EMR ON ONDO WHAT IS XBULLRADAR?

// MORE TICKERS

NVDA TSLA AAPL MSFT AMZN META GOOG COIN ALL TOKENIZED STOCKS →

Signals computed from cached market data (prices/fundamentals via FMP, refreshed up to every 6 hours) and are informational only. Not investment advice.